Diagnosis of bladder cancer from the voided urine specimens using multi‑target fluorescence in situ hybridization

Ke,Zunfu; Lai,Yuanhua; Ma,Xudong; Lil,Shuhua; Huang,Wenhua

doi:10.3892/ol.2013.1744

Diagnosis of bladder cancer from the voided urine specimens using multi‑target fluorescence in situ hybridization

Authors:
- Zunfu Ke
- Yuanhua Lai
- Xudong Ma
- Shuhua Lil
- Wenhua Huang
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Vascular and Thyroid Surgery, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China, Department of Anatomy, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: December 9, 2013 https://doi.org/10.3892/ol.2013.1744
Pages: 325-330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the diagnostic value of chromosomal analysis by fluorescence in situ hybridization (FISH) for bladder cancer in light of the histological diagnosis. Several valuable observations using FISH technologies in voided urine cells were also reported. The multi‑target FISH‑containing probes for the centromeres of chromosomes 3, 7 and 17 and the 9p21 locus were applied to cytospin specimens prepared from voided urine. Urine samples from 53 bladder cancer patients and 30 patients with benign alterations were used for this study. The histological observations of surgical resection specimens showed that the specificity and sensitivity for the technique were 100.0 and 88.0%, respectively. Statistical analyses showed that there was no significant correlation between FISH‑positive rate and the tumor stage/grade (P<0.05). However, the proportion of tumor cells with genetic abnormalities positively correlated with the tumor stage (P<0.01). Furthermore, the number of abnormal cells in muscle‑invasive pT2 was significantly higher than that in non‑muscle‑invasive pTa, pT1 (P<0.01). Of 50 patients with bladder cancer, polysomies of chromosomes 3, 7 and 17 were detected in 84.0, 48.0 and 78.0% of cases, respectively, and loss of the 9p21 gene was detected in 80.0% of cases. In addition, the detailed results from different urine specimens showed that FISH assay was required. FISH assay for chromosomes 3, 7 and 17 and 9p21 has a high speciﬁcity and sensitivity in the detection of bladder cancer and may reduce the necessity for cytoscopy treatment.

View Figures

View References

1	Chamie K and Litwin MS: Quality of bladder cancer care in the USA. Expert Rev Pharmacoecon Outcomes Res. 11:619–621. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V, et al; ESMO Guidelines Working Group. Bladder cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 22(Suppl 6): vi45–vi49. 2011. View Article : Google Scholar : PubMed/NCBI
3	Alameddine M and Nassir A: The influence of urine cytology on our practice. Urol Ann. 4:80–83. 2012. View Article : Google Scholar : PubMed/NCBI
4	Mian C, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Lusuardi L, et al: Liquid-based cytology as a tool for the performance of uCyt⁺ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology. 14:338–342. 2003. View Article : Google Scholar : PubMed/NCBI
5	Dahmoush L and Cohen MB: FISHing and beyond in urinary cytology. Diagn Cytopathol. 31:2012004. View Article : Google Scholar : PubMed/NCBI
6	Lapray JF, Costa P, Delmas V and Haab F: The role of ultrasound in the exploration of pelvic floor disorders. Prog Urol. 19:947–952. 2009.(In French).
7	Mazo EB, Gazhonova VE and Chepurov DA: Three-dimentional echography in diagnosis and staging of urinary bladder cancer. Urologiia. May–Jun;6–12. 2005.(In Russian).
8	Hermann GG, Mogensen K, Toft BG, Glenthøj A and Pedersen HM: Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol. 46:31–36. 2012. View Article : Google Scholar
9	Panani AD, Kozirakis D, Anastasiou J, Babanaraki A, Malovrouvas D and Roussos C: Is aneusomy of chromosome 9 alone a valid biomarker for urinary bladder cancer screening? Anticancer Res. 26:1161–1165. 2006.
10	Leonardo C, Merola R, Orlandi G, Leonardo F, Rondoni M and De Nunzio C: C-erb-2 gene amplification and chromosomal anomalies in bladder cancer: preliminary results. J Exp Clin Cancer Res. 24:633–638. 2005.PubMed/NCBI
11	Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL Jr, Zhang HZ, et al: Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol. 118:259–268. 2010. View Article : Google Scholar : PubMed/NCBI
12	Chuang KL, Chuang HC, Ng KF, Chang YH, Wu CT, Chuang CK, et al: Urinary fluorescence in situ hybridization assay for detecting urothelial carcinoma in Taiwanese patients. BJU Int. 105:1413–1416. 2010. View Article : Google Scholar : PubMed/NCBI
13	Reid-Nicholson MD, Ramalingam P, Adeagbo B, Cheng N, Peiper SC and Terris MK: The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder. Mod Pathol. 22:119–127. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
15	Madeb R, Golijanin D, Knopf J, Davis M, Feng C, Fender A, et al: Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology. 75:20–25. 2010. View Article : Google Scholar : PubMed/NCBI
16	Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM and Kurth KH: Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 169:1975–1982. 2003. View Article : Google Scholar : PubMed/NCBI
17	Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, et al: A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 167:2001–2006. 2002. View Article : Google Scholar
18	Galván AB, Salido M, Espinet B, Placer J, Pijuan L, Juanpere N, et al: A multicolor fluorescence in situ hybridization assay: a monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study. Cancer Cytopathol. 119:395–403. 2011.
19	Fritsche HM, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W, et al: Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol. 134:597–603. 2010. View Article : Google Scholar : PubMed/NCBI
20	Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM and Wolff DJ: Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 96:1280–1285. 2005.
21	Dumache R, David D, Kaycsa A, Minciu R, Negru S and Puiu M: Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer. Rev Med Chir Soc Med Nat Iasi. 115:163–167. 2011.
22	Song MJ, Lee HM and Kim SH: Clinical usefulness of fluorescence in situ hybridization for diagnosis and surveillance of bladder cancer. Cancer Genet Cytogenet. 198:144–150. 2010. View Article : Google Scholar : PubMed/NCBI
23	Kwak KW, Kim SH and Lee HM: The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice. J Korean Med Sci. 24:1139–1144. 2009. View Article : Google Scholar : PubMed/NCBI
24	Waldman FM, Carroll PR, Kerschmann R, Cohen MB, Field FG and Mayall BH: Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res. 51:3807–3813. 1991.
25	Sauter G, Simon R, Bubendorf L and Mihatsch M: Molecular genetics of urinary bladder cancer progression. Verh Dtsch Ges Pathol. 86:49–56. 2002.(In German).
26	Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G and Stenzl A: Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol. 43:461–466. 2009. View Article : Google Scholar : PubMed/NCBI